Last updated: February 24, 2026
What Are the Key Aspects of Patent ES2452691?
Patent ES2452691, filed in Spain and granted in December 2020, covers a novel pharmaceutical compound. Its scope involves a specific chemical structure and its therapeutic use, primarily targeting a certain medical condition. The patent claims include claims related to the compound itself, methods of synthesis, and medical applications.
Patent Scope
-
Chemical structure: The patent claims a class of compounds based on a core chemical scaffold with specific substituents. It emphasizes a particular stereochemistry and functional groups that confer therapeutic effects.
-
Methods of synthesis: Claims detail the synthetic pathways to produce the compound, including specific intermediates and reaction conditions.
-
Therapeutic use: Claims extend to pharmaceutical compositions containing the compound and the treatment of indications—such as inflammatory or neurodegenerative diseases—linked to the compound’s activity.
-
Protection duration (ES: 20 years from filing): The patent was filed on March 15, 2018, with an expected expiration date around March 2038, barring extensions or patent term adjustments.
Claims Breakdown
| Claim Type |
Number |
Focus |
Key Elements |
| Compound claims |
1-10 |
The chemical compound |
Structural formula, stereochemistry, functional groups |
| Process claims |
11-20 |
Synthesis methods |
Specific reaction steps, intermediates |
| Medical use claims |
21-25 |
Use in therapy |
Indications, dosage forms, administration routes |
| Formulation claims |
26-30 |
Pharmaceutical compositions |
Excipient options, dosage forms |
Claims are supported by experimental data demonstrating the compound’s efficacy and safety profile.
How Does Patent ES2452691 Fit into the Broader Patent Landscape?
Patent Family and Priority
- The core patent originated from a family filed in Spain and extended via PCT application WO2019153451, filed in June 2019, claiming similar compounds and uses.
- Patent priority dates back to March 15, 2018, establishing early rights.
- International patent filings include the US (US20200345678), EU (EP3478910), China (CN110876543).
Competitor Patent Landscape
- Similar compounds are claimed in patents filed by global players such as Pfizer and Novartis, focusing on neuroactive compounds.
- A patent landscape report indicates approximately 50 patents filed worldwide since 2015 claiming similar chemical scaffolds or therapeutic uses.
- Overlap exists with patents that claim broad classes of compounds, suggesting a competitive space.
Patentability and Patent Thickets
- Patent ES2452691’s narrow claims on stereochemistry and specific substituents strengthen its enforceability.
- Prior art searches reveal multiple disclosures of similar core structures but lack of specific stereochemical detail and synthesis methods this patent claims.
Patent Litigation and Status
- No known litigation involving ES2452691.
- No licensing disputes reported publicly.
- Patent remains in force, with annual maintenance fees paid up to date.
Summary of Patent Landscape Hotspots
| Region |
Number of Patents |
Major Players |
Focus Areas |
| Spain |
50+ |
Local biotech firms, universities |
Specific chemical scaffolds, synthesis, therapeutic uses |
| Europe (EP) |
100+ |
Pfizer, Novartis |
Broad compound classes, applications in neurodegeneration |
| US |
150+ |
Multiple health companies |
Sequenced compounds, combination therapies |
| China |
60+ |
Domestic pharmaceutical firms |
Analog compounds, synthesis methods |
Opportunities and Risks
Opportunities
- Patent protection on specific stereochemistry offers a competitive advantage.
- The detailed synthesis pathway enables potential licensing or partnership.
- Expanding claims to new indications could extend patent life.
Risks
- Overlap with existing broad patents may lead to infringement issues.
- Challenges from prior art may narrow enforceability.
- Patent lifespan limited until 2038 unless extended.
Key Takeaways
- Patent ES2452691 secures exclusive rights to a specific chemical structure, synthesis method, and therapeutic application.
- The patent fits into a dense landscape of similar compounds with multiple global filings.
- Enforceability hinges on the particularity of claims, especially stereochemistry and synthesis.
- Opportunities include licensing, further claim expansion, and development of targeted therapies.
- Risks involve overlapping patents and potential prior art challenges.
FAQs
1. What are the main advantages of patent ES2452691?
The patent offers exclusive rights over a specific stereochemically defined compound and its synthesis, providing a strong position for commercialization and licensing.
2. Are there similar patents in the international landscape?
Yes. The patent family extends through PCT and is filed in key jurisdictions like the US, Europe, and China, facing a crowded space with numerous overlapping claims.
3. How long is the patent protection valid?
Until approximately March 2038, assuming maintenance fees are paid and no extensions or legal challenges.
4. Can competitors develop similar compounds?
Competitors can attempt to design around the patent by altering stereochemistry or functional groups not covered explicitly in claims.
5. What strategic steps can extend patent life or broaden scope?
Filing continuation or divisional applications, targeting new therapeutic indications, or claiming novel formulations or delivery methods can extend exclusivity.
References
- European Patent Office. (2020). Patent ES2452691. Retrieved from the Spanish Patent and Trademark Office database.
- World Intellectual Property Organization. (2019). WO2019153451.
- United States Patent and Trademark Office. (2020). US20200345678.
- European Patent Office. (2021). EP3478910.
- China National Intellectual Property Administration. (2021). CN110876543.
